# Study of Safety and Immunogenicity of BVRS-GamVac

> **NCT04130594** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 162 (estimated)

## Conditions studied

- MERS (Middle East Respiratory Syndrome)
- MERS

## Interventions

- **BIOLOGICAL:** BVRS-GamVac
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT04130594
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-07
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-31
- **Target enrollment:** 162 (ESTIMATED)
- **Last updated:** 2021-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130594, "Study of Safety and Immunogenicity of BVRS-GamVac". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04130594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*